# Council Memo — 2026-11-09

*This memo is a structured synthesis of your own agents' analysis. It is not licensed investment advice.
Every number comes from one of these sources, read this session:*
- *this sweep's snapshot (`20261109T060852.json`)*
- *the candidates CSV (`20261109T061029-candidates.csv`)*
- *`candidate_history.csv` (the 11-02 and 11-09 blocks)*
- *the calendar file (`20261109-events.json`)*
- *`investor_profile.json`, `OPEN_ITEMS.md`, and the 2026-11-02 memo (for the standing calls I re-decide here)*
- *the four lens outputs relayed this session*

*Anything else is labelled as my arithmetic. FX is `sek_per_usd` 9.8320, dated 10-30.*

*The Council is still not weighted (OPEN_ITEMS: "The Council must not be weighted yet"). I judged arguments on their quality. Mechanical rank carries no evidential weight (S33).*

---

## What leads this memo

**1. A one-week sell-off in AI and memory hardware hit the top of the funnel. Low-beta names rose over the same week.**

Week on week (`candidate_history.csv`, 11-02 → 11-09, my arithmetic):

| Fell | Change |
|---|---|
| SNDK | −39.4% |
| MU | −29.7% |
| AMD | −28.6% |
| FIX | −27.2% |
| BE | −24.6% |
| ASML | −19.0% |
| TSM | −18.2% |
| AVGO | −15.5% |
| NVDA | −15.0% |

| Rose | Change |
|---|---|
| AZN.ST | +8.1% |
| PEP | +6.7% |
| KO | +3.1% |
| MA / V | +3.2% / +2.9% |

- VIX went from 17.20 to **28.18**, and Fear & Greed from 37 to 29.
- Scout's frozen top 5 is SNDK, NVDA, APP, MU, WDC. Four of the five are memory or AI-hardware names, and three of those four fell 15–39% this week.
- This is the scenario last week's Defensive voice positioned for ("an AI-capex unwind"). Most of this memo is about which conclusions that changes and which it does not.

**2. Two standing BUYs in the funding queue are withdrawn, and one is kept.**
- **AZN.ST** leaves the queue on portfolio fit. One more share would take Healthcare/UK above 45%.
- **SHB-A.ST** leaves on valuation. There is also no new insider evidence: the "larger volumes" `thesis-review` reports are the same 1.6M-share trade counted last week (§3a, Copycat).
- **NVDA** stays BUY, 1 share. Its print is on **11-17**, eight days away.

The new queue is in §5.

**3. Process note (S27): this is at least the 12th occurrence.** This week's scheduled prompt again claimed two things:
- that the Handelsbanken wrapper is unresolved. It was resolved 2026-08-03.
- that `reference_targets` are null. They are populated, just stale (S35).

The orchestrator declined both premises before anything ran. I am not re-arguing the wrapper.

---

## 1. Position report

```
## Position report — 2026-11-09

Snapshot: `20261109T060852.json` · previous: `20261102T061301.json`

| Position | Price | Δ vs prev snapshot | Δ vs cost | 52w range | Value (SEK) | Source |
|---|---|---|---|---|---|---|
| Handelsbanken A (stock) | 161.20 | +3.5% | +24.7% | 97% | 161.20 | fetched |
| Investor A (stock) | 423.40 | +0.9% | +45.9% | 94% | 2,117.00 | fetched |
| Volvo B | 316.80 | +2.2% | -13.8% | 52% | 4,118.40 | fetched |
| Atlas Copco B | 161.10 | -1.9% | -11.1% | 52% | 4,349.70 | fetched |
| AstraZeneca | 1,860.50 | +8.1% | +21.0% | 86% | 14,884.00 | fetched |
| Xetra-Gold (physically-backed gold ETC, ISIN DE000A0S9GB0) | no data | no data | no data | - | 5,689.22 | FETCH FAILED |
| Alfa Laval | 539.40 | -1.9% | -6.1% | 67% | 4,854.60 | fetched |
| ABB | 810.80 | -7.7% | -14.4% | 41% | 3,243.20 | fetched |
| Avanza Auto 3 (fund) | no data | no data | +65.2% | - | 16,191.00 | book value |
| Avanza Global (fund) | no data | no data | +0.0% | - | 119,999.00 | book value |
| Valour Bitcoin Zero SEK (certificate, ISIN CH0585378661) | no data | no data | no data | - | 11,031.00 | FETCH FAILED |
| ETH (self-custody wallet) | 20,961.89 | -7.8% | no data | - | 10,519.72 | fetched (CoinGecko, converted via sek_per_eur) |

*52w range: 0% = at the 52-week low, 100% = at the 52-week high.*

### Crypto context (spot, from CoinGecko)

| Coin | Price (EUR) | Δ vs prev snapshot | 7d | 30d | vs ATH |
|---|---|---|---|---|---|
| bitcoin | 66,788.00 | -4.5% | -5.0% | -9.9% | -38.0% |
| ethereum | 1,909.88 | -6.6% | -7.1% | -14.7% | -54.8% |

*Bitcoin is the agreed directional proxy for the XBT certificate, which has no working ticker. It indicates direction, not the certificate's actual price — that comes from the user.*
```

**Reading.**
- **The direct stock sleeve rose to 33,728.10 SEK**, up from 32,944.95 (my arithmetic). Almost all of the gain is AZN.ST: +140 SEK × 8 shares = **+1,120 SEK**. That is what a 0.155-beta holding should do in a week when VIX rose 11 points. It also used up the "~20% off the 52-week high" discount that was the stated entry case (#2).
- **ABB fell −7.7%.** No fundamental field moved enough to explain it: PEG went 1.24 → 1.19 and revenue growth held at +14.3%. None of the three reinstatement triggers set last week fired (§3c).
- **No move contradicts a holding's thesis.**
- **Crypto:** ETH −7.8% and BTC −4.5% (direction only), consistent with Fear 29.
- **Index funds:** still at book marks 15–16 weeks old (S39). That is a pricing gap, not a thesis issue.

---

## 2. Scout health

```
Universe: 624 | Fetched: 621 (cache 0, new 625, failed 4) | Ranked: 612 | Candidates: 76 (holdings 9/watchlist 30/new 37) | Focus: 24 | Screened: 76 | Passed: 43 | Missing: 16 | Failed: 17 | Status: VALID
```

**Reading: VALID. This week the funnel did surface names it had not shown last week.**

**Discovery.** I compared this CSV with the 11-02 block of `candidate_history.csv`:
- **12 names entered:** APA, APTV, CME, CPT, ECHO, EOG, MPC, PLTR, RDDT, VLO, VRT, WDC.
- **9 dropped out:** ALL, APO, AXON, CATE.ST, EG, FISV, FSLR, SMCI, UHS.
- **First-seen across all runs:** confirmed only for **WDC, ECHO and MPC**, per the orchestrator's relayed scout history. I did not check the other nine against the full file.
- Last week genuinely new names were zero, so this is better. S38 still applies, because the `new` label still means "not held or watchlisted".

**Things to distrust in §3:**
- **Suspect values are withheld from the lens scores, and I do not reason from them:**
  - SNDK and MU `revenue_growth` (~378%)
  - TSM and ASML `roic_pct` (257% and 544%)
  - ASML `price_to_book`
  - INDU-C.ST operating margin (102%)
  - KINV-B.ST `price_to_sales`
- **TSM's `fcf_yield_pct` of 61.78% is unflagged** (S32). I do not use it.
- **New finding: on this week's big movers, the P/E fields and the `price` column are not from the same moment.** This is my arithmetic, derived from price ÷ P/E on 11-02 and 11-09. The implied trailing and forward EPS each moved by the *same* percentage:

  | Name | Trailing EPS | Forward EPS |
  |---|---|---|
  | NVDA | −6.8% | −6.8% |
  | MU | −9.9% | −9.9% |
  | SNDK | −16.4% | −16.3% |
  | AVGO | −6.2% | −6.2% |
  | FIX | −11.9% | −11.5% |

  Real earnings revisions do not hit two different fiscal years by an identical amount. The likely cause is that the multiples were computed at a price higher than the `price` column.
  - **The forward/trailing ratios are still valid.** The absolute multiples on the fallers are overstated by roughly the percentages above.
  - APP is the exception: −6.9% trailing against −15.6% forward. That gap is real and comes from its 11-04 print (#4).
- **Four fetches failed.** Two are the standing S1 pair (BTC0E.AS and Xetra-Gold). The relay does not name the other two, and I did not open the scout JSON to find them.

---

## 3. Top opportunities

### 3a. The seven voices (independent passes)

Each voice triaged all 76 rows on its own columns. Names pulled in from outside `focus=Y` are labelled.

#### Voice 1 — Fundamental / Quality

*Triage (`z_quality`):*

| Name | z_quality | Name | z_quality |
|---|---|---|---|
| SNDK | 2.555 | TPL | 1.769 |
| NVDA | 2.538 | AZA.ST | 1.730 |
| APP | 2.532 | LLY | 1.650 |
| MU | 2.488 | AAPL | 1.619 |
| WDC | 2.293 | MO | 1.539 |
| MA | 2.236 | | |
| V | 1.926 | | |

*Moat, management and capital allocation are not in any fetched field. Where I rely on them, I say so.*

- **BUY V, 8.**
  - Why: ROIC 41.3%, ROE 63.5%, margins 51.2/63.7, ND/EBITDA 0.28, revenue +13.2% on a 12.0% CAGR. The price rose +2.9% in a week when quality-tech fell 15–39%, which is real evidence the earnings are not tied to the capex cycle.
  - Risk: interchange regulation (qualitative).
  - Invalidated by: ROIC below 30%, or revenue growth below the CAGR for two runs.
- **BUY MA, 7 (overriding its FAIL).**
  - Why: D/E 355 reflects buyback-driven negative equity. ND/EBITDA is 0.59, ROIC 56.6%, revenue +14.0%.
  - Invalidated by: ND/EBITDA above 2.0.
- **BUY APP, 7 (up from 6).**
  - Why: the print passed my quality test. Op margin is 78.2% (it was 77.7%), ROIC 72.2%, ND/EBITDA 0.06. FCF yield of 2.87% against an earnings yield of 3.80% means ~76% cash conversion (my arithmetic).
  - Risk: the price is up 39.7% in a week. Quality is a fact about the business, not about the entry price.
  - Invalidated by: op margin below 60%.
- **BUY NVDA, 7.**
  - Why: ROIC 59.2%, ROE 117.2%, op margin 66.2%, net cash (−0.12).
  - What caps the conviction: FCF yield is 0.93% against an earnings yield of 4.24%, so only ~22% of earnings reaches free cash. That has not changed.
  - Invalidated by: FCF yield still below 1% after the 11-17 print.
- **BUY ATCO-B.ST (holding), 6.**
  - Why: ROIC 38.5%, op margin 20.8%, ND/EBITDA 0.3, a clean SEK FCF yield of 3.32%. TTM revenue +15.1% holds for a third run.
  - Invalidated by: TTM revenue turning negative.
- **Declined:**
  - **SNDK, MU, WDC.** Op margins of 79.6/80.7/47.7 are cycle-peak numbers. This week's −39%/−30% moves show the market reading them that way. WDC's net margin of 69.2% is above its op margin of 47.7%, so non-operating income is in the earnings.
  - **TPL.** Its forward figure is incoherent.
  - **AZA.ST.** Forward 28.3 against trailing 20.0 implies EPS −29%.
- **SELL: none.**

#### Voice 2 — Valuation

*Triage (`z_value`):*

| Name | z_value | Name | z_value |
|---|---|---|---|
| FIS | 1.881 | CHTR | 1.573 |
| MPC | 1.798 | APA | 1.505 |
| CMCSA | 1.692 | GM | 1.495 |
| CORE-B.ST | 1.643 | BURE.ST | 1.420 |
| APTV | 1.638 | SNDK | 1.382 |
| VLO | 1.602 | | |
| DOM.ST | 1.596 | | |

*Named gap: there is no EV/EBITDA. Where I lean on ND/EBITDA, I say so.*

- **BUY NVDA, 7.**
  - Why: forward 11.73 against trailing 23.60, a ratio of 0.497, on revenue +105.9%.
  - Both implied EPS legs fell by the same 6.8% (§2), so there is **no visible estimate cut**. The −15% move is pure price. Assuming EPS is unchanged, the forward multiple at today's price is ~10.9 (my arithmetic).
  - Invalidated by: forward rising above trailing, or the 11-17 print cutting forward EPS relative to trailing.
- **BUY VOLV-B.ST (holding), 6.**
  - Why: forward 12.56 against trailing 16.28, PEG 0.86, FCF yield 3.82%, dividend 2.72%, 52% of range.
  - Watch item: ND/EBITDA 3.69.
  - Invalidated by: forward rising to meet trailing.
- **BUY MPC, 5 (new, first-seen).**
  - Why: 7.39x trailing and 6.07x forward. FCF yield is 16.0% (USD over USD, so clean) against an earnings yield of 13.5%, meaning cash conversion is above 100%. ND/EBITDA 0.88, ROIC 43.4%, beta 0.509.
  - Risk, and it is the whole risk: revenue is +60.9% on a −9.1% 3-year CAGR. That is a cyclical rebound, and no crack-spread or commodity data is fetched to tell me whether the 6x is on peak margins.
  - VLO (7.88/6.48, FCF 13.0%, ND/EBITDA 0.06) is the same bet with a cleaner balance sheet. I would own one, not both.
  - Invalidated by: forward rising above trailing.
- **SELL ABB.ST, 3 (unchanged).**
  - Why: 31.17x trailing and 30.67x forward is still the richest pair held. The flat gap means flat expected EPS on +14.3% revenue.
  - Conceded again: PEG 1.19 is the cheapest of the three industrials, and the −7.7% week made the price better, not worse.
- **Examined, not picked:**
  - **FIS.** Down 21% to 3% of range. Forward 5.11 is above trailing 4.29, implying EPS −16%. Net margin 26.8% is above op margin 22.9%, and ND/EBITDA is 5.43. The low multiple is mostly non-operating income. Value trap.
  - **APTV.** 11.0/6.5 and FCF yield 19.4% at 3% of range, but net margin is 3.7% and revenue +2.3%. One run of evidence. Watch.
  - **GM.** FCF yield 38.99% with D/E 202.6. I do not trust that FCF figure for a company that has a finance arm.
  - **CMCSA / CHTR.** Revenue −6.1%, and CHTR's D/E is 368.6.
  - **SNDK.** 6.7x/2.9x at a 79.6% op margin is exactly what a cycle peak looks like. No PEG.

#### Voice 3 — Growth / Opportunity

*Triage (`z_growth`):* NVDA 1.959, AVGO 1.793, PLTR 1.755, BE 1.716, FIX 1.605, VRT 1.572, MU 1.518, DASH 1.433, APP 1.395, LLY 1.341.

*Forward below trailing (forward / trailing):*

| Name | Forward / trailing |
|---|---|
| NVDA | 11.73 / 23.60 |
| RDDT | 10.24 / 19.41 |
| AVGO | 15.09 / 37.51 |
| FIX | 15.17 / 21.98 |
| VRT | 18.58 / 34.18 |
| APP | 18.90 / 26.34 |
| VOLV-B.ST | 12.56 / 16.28 |

*Not trusted:*
- SNDK and MU growth (suspect-flagged)
- AVGO (an acquisition base effect, per last week's Valuation read)
- PLTR and BE (both FAIL, and BE fell 24.6%)

*Named gaps: no TAM, earnings-revision or market-share data.*

- **BUY NVDA, 8.**
  - Why: +105.9% on a 100.0% CAGR, with forward at half of trailing. The week's −15% came with no implied estimate change (§2).
  - Risk: the sell-off across AMD, MU, TSM, ASML and AVGO is the market pricing a capex slowdown that measured growth does not yet show. Either the market or the fields are early.
  - Invalidated by: growth below 40% at 11-17, or forward rising above trailing.
- **BUY APP, 5.**
  - Why: revenue accelerated to +55.5% (it was +52.8%).
  - Against: implied EPS growth (forward vs trailing) fell from **+54% to +39%** (ratio 0.650 → 0.717, my arithmetic). So the print *lowered* expected growth while the price rose 40%.
  - Invalidated by: the ratio rising above 0.80.
- **BUY FIX, 5 (down from 6, pulled in at rank 22).**
  - Why: revenue +53.7% on a 30.0% CAGR, forward 15.17 against 21.98, net cash (−0.81), and FCF yield 5.94% above an earnings yield of 4.55%.
  - It fell 27.2% with no implied estimate change, so this is de-rating, not deterioration.
  - Lowered because its sell-off shows how crowded the data-centre trade is (beta 1.643).
  - Invalidated by: growth below 25%.
- **BUY RDDT, 4 (pulled in at rank 46, new to the set this week).**
  - Why: revenue +53.0%, forward 10.24 against 19.41, net cash (ND/EBITDA −3.25), and FCF yield 4.42% against an earnings yield of 5.15% (~86% conversion).
  - Risk: the price is at 3% of range and no fetched field explains why. The 3-year CAGR is null and the beta is 2.275.
  - Invalidated by: the forward multiple rising to meet trailing.
- **SELL SHB-A.ST, 3.** Revenue −2.1% for a third run, forward 14.01 above trailing 13.59, z_growth −1.162.
- **Declined:**
  - **VRT.** The same data-centre driver as NVDA and FIX. A third pick on one driver adds no information.
  - **AVGO.** Base effect.
  - **PLTR.** 112.9x trailing.

#### Voice 4 — Defensive / Risk

*Triage (lowest `beta`):*

| Name | Beta | Name | Beta |
|---|---|---|---|
| SAAB-B.ST | 0.012 | APA | 0.282 |
| BETS-B.ST | 0.123 | PEP | 0.321 |
| AZN.ST | 0.155 | PG | 0.361 |
| CME | 0.184 | NOVO-B.CO | 0.368 |
| ABBV | 0.192 | EXE | 0.370 |
| JNJ | 0.200 | | |
| KO | 0.269 | | |
| EOG | 0.269 | | |

**Scenarios.** Last week I positioned for an AI-capex unwind. Part of it arrived: the hardware names fell 15–39% and VIX reached 28.18. The scenario I now worry about is the next leg:
- the sell-off spreading from hardware to the wider growth complex, under a dollar index of 121.67.

- **BUY AZN.ST, 6 (down from 7).**
  - Why: beta 0.155, ND/EBITDA 1.23, op margin 29.6%. It rose 8.1% in exactly the week it was bought for.
  - Lowered because the cushion it offered is now partly spent (86% of range).
  - Invalidated by: op margin below 20%, or a dividend cut.
- **BUY CME, 5 (new to the set this week).**
  - Why: beta 0.184, op margin 65.9%, ND/EBITDA 0.31, revenue +13.0%.
  - *Qualitative, labelled as such:* exchange volumes tend to rise with volatility, so this is a name that can *gain* in my scenario, not just fall less.
  - Risk: PEG 4.22 and 80% of range. You pay up for the hedge.
  - Invalidated by: revenue growth turning negative while VIX stays above 25. That would disprove the mechanism.
- **BUY PEP, 4.**
  - Why: beta 0.321, dividend 4.19%, forward 16.36 below trailing 17.78. It rose 6.7% this week.
  - Risk: D/E 230.7 (ND/EBITDA 2.12).
- **BUY NOVO-B.CO, 4.**
  - Why: beta 0.368, ND/EBITDA 0.49, P/E 10.57, dividend 4.34%, 25% of range.
  - Risk: forward 11.89 is above trailing, so EPS is expected to fall about 11%.
- **SELL VOLV-B.ST, 3.** D/E 140.9 and ND/EBITDA 3.69 at beta 1.016, in a regime that `macro-regime` calls risk-off. Unchanged.
- **Attacking the BUY cases:**
  - **NVDA, APP, RDDT, FIX.** Betas 2.247 / 2.498 / 2.275 / 1.643. This week showed the downside in one-week numbers, not hypotheticals.
  - **MPC.** It passes on balance sheet (beta 0.509, ND/EBITDA 0.88), but a refiner's earnings are commodity-beta, and equity beta does not capture that.
  - **SHB.** At 97% of range there is no cushion.

#### Voice 5 — Contrarian / Risk Taker

*Triage (`pct_52w_range`):*

| Name | % of range | Name | % of range |
|---|---|---|---|
| AVGO | 1 | FIX | 10 |
| TPL | 2 | VRT | 12 |
| FIS | 3 | CHTR | 16 |
| APTV | 3 | WDC | 20 |
| RDDT | 3 | WIHL.ST | 20 |
| EXE | 5 | NVDA | 22 |
| GOOGL | 9 | NOVO-B.CO | 25 |
| CORE-B.ST | 10 | | |

- **BUY AVGO, 4 (watchlist, focus).**
  - Why the pessimism looks wrong on the data: it fell 15.5% to **1% of range**, yet both implied EPS legs moved by an identical −6.2%, so no estimate cut is visible. Op margin is 54.3%, ND/EBITDA 0.68. GAAP FCF yield of 2.18% against a GAAP earnings yield of 2.67% means ~82% conversion.
  - Risk: the market may be pricing the capex peak before any field shows it.
  - Invalidated by: the **12-09** print cutting forward EPS relative to trailing.
- **BUY NOVO-B.CO, 4.** At 10.6x with a 33.9% net margin, the price discounts more than the ~11% EPS decline the forward implies. Invalidated by: revenue turning negative.
- **BUY GOOGL, 3.**
  - Why: the price held flat (283.82 → 282.57) through a week when large-cap tech fell, still at 9% of range. Revenue +24.7%.
  - The trailing figure is flattered by non-operating income (net margin 50.0% against op margin 31.8%).
  - Bear point: FCF yield is −0.03%.
- **Retired: APP.** The price/fundamentals divergence I bet on resolved the way I expected (+39.7%). At 26% of range, after the move, there is no contrarian case left.
- **Declined, penalty deserved:**
  - **MU, SNDK, WDC.** "Cheap after a crash" at a 3–9x multiple on peak margins is the textbook cyclical trap. No memory-pricing data is fetched, so I cannot say the pessimism is wrong.
  - **FIS.** See Valuation.
  - **ECHO.** Revenue −68.8%, net margin 81.3% against op margin 13.8%, FCF yield −8.28%. The 3.4x P/E is a one-off.
  - **WIHL.ST / DIOS.ST.** I re-tested them as promised. The Riksbank held at 1.75% (dated 11-06), so the event risk passed. But ND/EBITDA of 10.78 and 9.88 is unchanged, and the real policy rate is still +0.65pp.
- **SELL: none.**

#### Voice 6 — Macro / Regime

*Regime (`macro-regime`): RISK-OFF.*
- **Drivers:** VIX 28.18 (17.20 last week), DXY 121.67 (121.32), Fear & Greed 29.
- **Tension, kept visible:** the 10y–2y spread is +0.38 (10y 4.84, 2y 4.46), positively sloped and not inverted. "Late-cycle stress, not yet recession-signalling."
- **Riksbank:** held at 1.75% through 11-04, so the binary I flagged resolved as no change. The Swedish real rate is +0.65pp; the US real rate is −0.14pp.

*Named gaps:*
- no commodity-price or credit-spread data
- FX dated 10-30 (10 days old, *before* the VIX spike)
- the fed funds rate is October's monthly average, so the 10-28 FOMC outcome is not cleanly in it.

- **BUY AZN.ST, 6 (up from 5).** Low beta and USD reporting suit risk-off. **This upgrade is on regime alone.** Its fundamentals did not change.
- **BUY DE000A0S9GB0 (Xetra-Gold, tranche 2), 6.** Risk-off is the regime the crash-hedge carve exists for. There is no live price (S1), so I cannot confirm it behaved as a hedge this week.
- **BUY CME, 4.** USD-earning, low beta. Volatility helps the business model (qualitative).
- **NVDA: no BUY this week. This is a regime-only downgrade, stated plainly.** Its fundamentals are unchanged. A beta of 2.247 in a VIX-28, strong-dollar regime is the profile that keeps de-rating until the regime turns. That is not a fundamental objection.
- **Abstaining on energy (MPC, VLO, APA, EOG).** Four energy names entered the set together, which points to one commodity driver I have no data on.
- **Crypto: no adds.** A strong dollar plus Fear 29 is the wrong side of this regime. That is not a trim signal (D-c).
- **SELL flags on macro alone: none.** The high-beta industrials (VOLV, ATCO, ABB at ~1.0–1.07) are on the wrong side, but a regime read does not justify a sale.

#### Voice 7 — Copycat / Smart Money

**Coverage:**
- **US:** SEC EDGAR returned 403 again (CIK mapping). **Zero US insider data.**
- **Sweden:** FI covered only the 7 holding issuers. There is **no read on any non-holding candidate**, including AZA.ST.
- **Institutions:** `MISSING: institutional ownership not fetched`.

This voice can only speak to holdings this sweep.

**Correction to `thesis-review`.** It says Boman and Lindh are "buying even larger volumes than previously flagged". The snapshot's eight Boman rows on 27/10 sum to exactly **1,600,000 shares** (my arithmetic). That is the same total the 11-02 memo counted. Lindh's two identical 20,000 @ 147.7409 rows are the same pair, likely a duplicate, already noted last week. **No new SHB transaction exists.** Likewise, Stjernholm's eight Volvo rows sum to the same **1,500,000** as last week. Old evidence carried forward is not new evidence.

**Correction to `thesis-review` on ABB.** The 02/11 allotment covers **10** directors, not 11. All are at an identical 79.24 CHF on one date. That is board-fee compensation, as `thesis-review` correctly reads. It is the second instance of this pattern (see OPEN_ITEMS, "Considered, not opened").

- **BUY VOLV-B.ST, 7 (down from 8).**
  - Why: it is still the largest insider purchase on record here. The price of 316.80 is only ~2% above her ~310 entry.
  - Lowered because it is a week older with no follow-up.
  - Invalidated by: any disposal from this holder.
- **BUY ATCO-B.ST, 6.**
  - Why: CEO Rego 6,400 @ 156.80, CFO Kinnart 4,000 @ 159.35, Deputy CEO Andersson 5,000 A @ 181.82, board member Forssell 10,000 @ 158.65. Four roles, independent decisions. The price of 161.10 is within ~1–3% of three of those entries.
- **BUY SHB-A.ST, 5 (down from 7).**
  - Why: the same chairman purchase, ~245M SEK at ~153 (my arithmetic, carried forward).
  - Lowered because the price is now 161.20, ~5% above his entry, and nothing has been added since.
- **No call:**
  - **AZN.** Soriot's 60,000 @ 121.02 GBP is 8 weeks old. The 0.00-priced rows are vestings.
  - **INVE.** Nodhäll's rows are a share-class switch.
  - **ALFA.** CFO Ekström 1,000 @ 547.49 on 11/09 is the latest. The pattern is intact but quiet.
  - **ABB.** Compensation allotment.
- **SELL flags: none.**

---

### 3b. Chairman's Top 5

Rank is reported for persistence only (S33).

#### #1 OPPORTUNITY: NVDA — Nvidia

**CATEGORY:** watchlist

**RANK HISTORY:** 2 now; 2 on 11-02. Top-10 in 12 of 12 runs (scout relay).

**VOICES IN FAVOR:**
- Growth, 8: +105.9% on a 100% CAGR, no estimate cut.
- Valuation, 7: forward/trailing 0.497, ~10.9x forward at today's price.
- Fundamental, 7: ROIC 59.2%, net cash.

**VOICES AGAINST / CAUTIOUS:**
- Macro: no BUY, a regime-only downgrade (beta 2.247 in risk-off).
- Defensive: the hardware sell-off is the downside arriving.
- Fundamental's caveat: FCF covers only ~22% of earnings.

**STRONGEST CASE FOR:** Valuation's. Price fell 15%, while both EPS legs moved by an identical −6.8%. That is the signature of a price-basis mismatch, not a revision (§2). The business the Council called a BUY at 213.66 is unchanged at 181.60.

**STRONGEST CASE AGAINST:** Defensive's. Nine names that share NVDA's demand driver fell 15–39% in one week. The market may be pricing a capex turn that trailing fields cannot show until a print. The print is 8 days away.

**KEY DISAGREEMENT:** Valuation says the price fell and the business did not. Macro says this is the regime in which high-beta growth keeps de-rating regardless. These are not the same claim, and they do not cancel. Macro's case does not dispute the fundamentals, and it is explicitly not a timing system. That is why the BUY survives. The 11-17 print settles whether the fields or the market were early.

**DATA GAPS:**
- no revision data
- no US insider data (SEC 403)
- no 13F
- absolute P/E levels uncertain by ~7% (§2)
- FX 10 days old

Moderate discount.

**CHAIRMAN CONVICTION:** 6 (unchanged)

**WHAT WOULD CHANGE THIS:**
- **Kills it:** at 11-17, the forward multiple rising toward trailing (estimates cut), or revenue growth below 40%.
- **Raises it:** FCF yield moving toward the earnings yield.

**PORTFOLIO FIT:**
- `portfolio`: "diversify sector (zero current Tech) + country/currency (zero direct US/USD stock exposure), cap-tier neutral... likely duplicate Avanza Global's own index exposure (overlap unverifiable, gap)."
- Pool-level flag from `portfolio`: 7 of the 15 focus candidates are Tech and 14 of 15 are US. **One share** answers the zero-Tech gap without swinging the sleeve to Tech-heavy.
- One share = 181.60 × 9.832 = **1,785.49 SEK** (my arithmetic), ~0.84% of the 212,510 SEK investable capital.

**FINAL CALL: BUY**, 1 share.

**Execution note:** idle ISK cash is 845 SEK (`portfolio`). This is funded by P3, second in the queue after gold. If P3 lands before 11-17 you buy into the print. That is acceptable at a Medium horizon. Do not time it.

**HORIZON:** Medium

#### #2 OPPORTUNITY: AZN.ST — AstraZeneca

**CATEGORY:** holding (standing BUY 1 share in last week's queue)

**RANK HISTORY:** 60 now; 58 on 11-02. Never top-10 (S21 records 59–62 across prior sweeps).

**VOICES IN FAVOR:**
- Defensive, 6: beta 0.155, op margin 29.6%.
- Macro, 6: risk-off fit, a regime-only upgrade.

**VOICES AGAINST / CAUTIOUS:**
- `thesis-review`: WEAKENING (captured upside). Would-buy-fresh: HOLD ONLY.
- Valuation (lens): Fair, PEG 1.35, with "86% of range limits margin of safety".

**STRONGEST CASE FOR:** Defensive's. In a week when VIX rose 11 points, it rose 8.1%. That is the job it was bought to do, done on schedule. Op margin of 29.6% and ND/EBITDA of 1.23 are unchanged.

**STRONGEST CASE AGAINST:** `thesis-review`'s. The stated entry claim, "priced ~20% off 52w high", is no longer true at 96.6% of the high. The business case holds, but the price case behind adding does not.

**KEY DISAGREEMENT:** Macro is upgrading a name *because* it just outperformed, while `thesis-review` downgrades the entry case for the same reason. I side with `thesis-review` on the *add* question. Buying more of a defensive after it has done its defensive job is paying for insurance after the claim. Macro's regime point is valid for *holding*.

**DATA GAPS:**
- `forward_pe` missing for a 12th run (S21)
- FCF/P/S/P/B still unit-mismatched (S32): 0.2% raw, ~2.0% corrected per S32's verification
- no next print date (10-30 returned as past)

**CHAIRMAN CONVICTION:** 6 on the business. Low on adding at this price.

**WHAT WOULD CHANGE THIS:** a pullback toward the middle of its range while op margin stays at or above 20%. Or Healthcare falling below ~40% of the direct sleeve after the queue lands.

**PORTFOLIO FIT:**
- `portfolio`: "largest actual single stock AZN.ST is 7.0%, clean". Healthcare is 44.1%, "WATCH/ACT border". UK is 44.1%.
- One more share takes Healthcare/UK to (14,884 + 1,860.50) / (33,728.10 + 1,860.50) = **47.0%** (my arithmetic). That **crosses the 45% ACT line** on both.

**FINAL CALL: HOLD-WATCH.** Hold all 8 shares and **withdraw the queued 1-share BUY.**

**Record update for you:** `thesis_status` INTACT → WEAKENING, per `thesis-review`. I concur, with one caveat: this is captured upside, not deterioration, and it is not a sell signal.

**HORIZON:** Medium

#### #3 OPPORTUNITY: SHB-A.ST — Handelsbanken A

**CATEGORY:** holding (1 share; standing BUY 10 shares, last in the queue)

**RANK HISTORY:** 42 now; 41 on 11-02. Never top-10 in the runs checked.

**VOICES IN FAVOR:** Copycat, 5: the chairman's ~245M SEK purchase at ~153.

**VOICES AGAINST / CAUTIOUS:**
- Growth: SELL 3. Revenue −2.1% for a third run, forward above trailing.
- Defensive: no cushion at 97% of range.
- Valuation (lens): Expensive, PEG 6.97.
- `thesis-review`: would-buy-fresh NO.

**STRONGEST CASE FOR:** Copycat's. A chairman's associated entity putting ~245M SEK into the stock is rare evidence. A four-insider cluster came before it (carried from 10-26).

**STRONGEST CASE AGAINST:** this sweep's own register. The evidence is **not new**. `thesis-review`'s "larger volumes" is the same 1.6M-share 27/10 trade, re-read. Meanwhile:
- the price rose a further 3.5% to 161.20, ~5% above the insider's entry
- revenue is −2.1% for a third run
- forward 14.01 is above trailing 13.59, so EPS is expected to fall.

**KEY DISAGREEMENT:** insider conviction against declining revenue at a 52-week high. Last week I kept the BUY at conviction 4 because the insider evidence had just *strengthened*. This week it did not strengthen; it was double-counted by a lens. The price moved against the entry. The case for adding has only weakened.

**DATA GAPS:**
- no bank NIM or credit-quality data
- FI duplicate rows (Lindh)
- no next print date

**CHAIRMAN CONVICTION:** 3 (on the add)

**WHAT WOULD CHANGE THIS:** a *new* insider purchase in a fresh FI pull, or a pullback toward the ~153 insider entry. A disposal by any of the five insiders would turn the Growth SELL into a live question.

**PORTFOLIO FIT:**
- `portfolio`: Financial Services 6.75% (clean), Sweden 46.3% (ACT).
- Ten shares (1,612 SEK) take Sweden to (15,600.90 + 1,612) / (33,728.10 + 1,612) = **48.7%** (my arithmetic). That worsens an ACT line.

**FINAL CALL: HOLD-WATCH.** Hold 1 share and **withdraw the queued 10-share BUY.** Growth's SELL is overruled: the position is 161.20 SEK, and selling it changes nothing.

**HORIZON:** Medium

#### #4 OPPORTUNITY: APP — AppLovin

**CATEGORY:** new candidate (`source=new`; in the funnel every run since 2026-08-25, not first-seen)

**RANK HISTORY:** 3 now; 3 on 11-02. Top-10 in 12 of 12.

**VOICES IN FAVOR:**
- Fundamental, 7: op margin 78.2% after the print, ND/EBITDA 0.06.
- Growth, 5: revenue +55.5% and accelerating.
- Valuation (lens): Cheap, PEG 0.85.

**VOICES AGAINST / CAUTIOUS:**
- Contrarian: retired (the divergence resolved).
- Defensive: beta 2.498.
- Growth's own caveat: implied EPS growth fell from +54% to +39%.

**STRONGEST CASE FOR:** Fundamental's. The print passed the op-margin half of my own pre-set test (above 70%) with room. A 78% margin business converting ~76% of earnings to cash, with net cash, at 18.9x forward.

**STRONGEST CASE AGAINST:** Growth's arithmetic against my own test. Last week I wrote: "forward rising toward trailing ends the case." The ratio moved 0.650 → 0.717. Expected EPS growth fell by about a quarter while the price rose 39.7%. The market paid more for less expected growth. That is the opposite of the setup the BUY case needed.

**KEY DISAGREEMENT:** an excellent business against a worse entry. The test I set gave a split result: margin passed, and the forward multiple moved partway toward trailing. I will not round a split result up to a pass because the business is good.

**DATA GAPS:**
- no 52-week endpoints (S29, closed)
- no US insider data
- no revenue-concentration data
- the trailing leg also rolled a quarter at the print, so the +39% comparison is approximate

**CHAIRMAN CONVICTION:** 5

**WHAT WOULD CHANGE THIS:**
- **Raises it:** the forward/trailing ratio falling back below ~0.68 at an unchanged or lower price.
- **Ends it:** the ratio above 0.80.

**PORTFOLIO FIT:**
- `portfolio`: "diversifies sector (Communication Services, new) + country/currency, cap-tier neutral."
- One share = 356.10 × 9.832 = **3,501.18 SEK** (my arithmetic). No capital is free after the §5 queue.

**FINAL CALL: HOLD-WATCH.** This re-decides last week's HOLD-WATCH with the print in the data. It is not promoted.

**HORIZON:** Medium

#### #5 OPPORTUNITY: MPC — Marathon Petroleum

**CATEGORY:** new candidate, **discovered this sweep** (first-seen per the scout relay)

**RANK HISTORY:** 10 now; first seen.

**VOICES IN FAVOR:** Valuation, 5: 7.4x/6.1x, FCF yield 16.0% above the earnings yield, ND/EBITDA 0.88.

**VOICES AGAINST / CAUTIOUS:**
- Growth: declined. +60.9% on a −9.1% CAGR is cyclical, not structural.
- Macro: abstains explicitly (no commodity or crack-spread data).
- Defensive: the balance sheet passes, but beta understates commodity risk.

**STRONGEST CASE FOR:** Valuation's.
- Cash conversion is above 100%.
- ROIC is 43.4%, beta 0.509, and the forward multiple is below trailing, so consensus expects earnings to *rise*.
- It is the only new, genuinely first-seen name whose numbers survive every voice's balance-sheet test.
- Energy is 0% of the portfolio.

**STRONGEST CASE AGAINST:** Growth's, sharpened by Macro.
- A refiner trading at 6x on a revenue rebound is exactly how cycle-peak earnings look.
- The 3-year revenue CAGR is −9.1%.
- Four energy names (MPC, VLO, APA, EOG) entered the funnel in the *same* sweep. That is one commodity driver, not four discoveries, and this system cannot see that driver.

**KEY DISAGREEMENT:** cheap on measured cash, against unmeasurable cyclicality. No file can tell whether these are mid-cycle or peak margins.

**DATA GAPS:**
- no crack spreads or commodity prices (named gap)
- one run of evidence
- no US insider data
- next print 2027-02-02

Heavy discount.

**CHAIRMAN CONVICTION:** 4

**WHAT WOULD CHANGE THIS:**
- A second and third run with forward still below trailing and FCF yield holding above ~10%, while the price is flat or lower, raises it.
- Forward rising above trailing ends it.

**PORTFOLIO FIT:**
- `portfolio`: "Energy is entirely absent from the portfolio, genuinely diversifies sector; [MPC/TPL] would overlap each other if both bought." The same applies to MPC/VLO.
- One share = 377.32 × 9.832 = **3,709.81 SEK** (my arithmetic).
- This is the one name in the set whose addition would also take Industrials below 45% of the direct sleeve after the queue (§5).

**FINAL CALL: HOLD-WATCH.** Re-test next sweep.

**HORIZON:** Medium

### 3c. Should you sell anything?

**No. The Chairman makes no SELL call this sweep.**

Voice SELLs that did not place:

- **ABB.ST (Valuation SELL 3; `thesis-review` BROKEN, would-buy-fresh NO). NO ACTION stands, conviction 5.** Last week's memo set three observables that would reinstate a SELL. I checked each one:
  - **Forward P/E above trailing?** No: 30.67 vs 31.17.
  - **Op margin below 16.9%?** No: 18.7%.
  - **A new insider disposal cluster?** No. The 02/11 rows are a 10-director compensation allotment.

  The −7.7% price move came with PEG improving to 1.19.
  - `thesis-review`'s BROKEN rests on "no differentiated reason to own" plus the flat forward gap. That argument is real, but it is the **same argument** the 11-02 memo already weighed and set aside. Re-asserting it after a falling week is not new evidence.
  - Selling now would also push Sweden from 46.3% to ~51.2% of the direct sleeve (15,600.90 / 30,484.90, my arithmetic), because ABB is the only non-Swedish industrial.
  - **Record update, still unapplied:** `thesis-review` read ABB's stored status as BROKEN, so last week's recommended edit (BROKEN → WEAKENING) has not been made.
- **VOLV-B.ST (Defensive SELL 3): overruled.**
  - Valuation, Copycat and `thesis-review` (INTACT, would-buy-fresh "YES BUT SMALLER") disagree, on the same data.
  - The leverage is unchanged since purchase.
  - Hold 13 shares and do not add (Industrials ACT).
  - **Record update, still unapplied:** TOO_EARLY → INTACT.
- **SHB-A.ST (Growth SELL 3):** overruled in #3.
- **INVE-A.ST:** the durable hold (D-b) stands until a NAV figure exists. At 94% of range, there is still no SELL voice.
- **ALFA.ST, ATCO-B.ST, the funds, Xetra-Gold, BTC0E.AS, ETH:** no SELL flag. ETH stays under the no-adds freeze (P1).

**Considered for the Top 5, not placed:**
- **SNDK / MU / WDC (mechanical #1, #4, #5).**
  - The quality lens ranks them on cycle-peak margins. This week the market marked SNDK −39% and MU −30%.
  - No voice picked them, and Contrarian explicitly declined: no memory-pricing data, so "cheap after a crash" is not a thesis.
  - This is a concrete S33 instance: the top of the mechanical rank is where cyclical peak earnings collect.
- **V / MA** (Fundamental 8/7). They rose ~3% in the sell-off, which is useful evidence of resilience. Valuation's PEG objection (1.91/1.70, ~87% of range) is unanswered.
- **CME** (Defensive 5, Macro 4). Two independent lenses, but new to the set this week and at PEG 4.22. Watch.
- **AVGO** (Contrarian 4). At 1% of range with no visible estimate cut. The 12-09 print, which is also FOMC day 2, is the test.
- **FIX** (Growth 5). Fell 27% with no field change. One share is ~9,487 SEK, in Industrials. HOLD-WATCH on fit, as before.
- **VICI.** It dropped from rank 28 to 37 with no voice support. HOLD-WATCH from last week is unchanged. No AFFO has been fetched.

---

## 4. Portfolio health scorecard

Carried from this sweep's `portfolio` lens.

| Dimension | Grade | Finding |
|---|---|---|
| Asset allocation vs targets (80/10/0/5/5) | WATCH | FI/alt sleeve +3.1pp over (largest drift, structural — Auto3's embedded bond/alt sleeve); gold -2.3pp under; cash +2.2pp over; equity -3.1pp, crypto +0.1pp both close to target |
| Equity sector concentration | ACT | Industrials 49.1% of the *verified* stock sleeve (33,728 SEK) — >45% threshold breached; true whole-sleeve number unverifiable (look-through gap on index fund/Auto3) |
| Geography (home bias) | ACT | Sweden 46.3% of verified stock sleeve — >45% threshold breached, same look-through caveat |
| Currency exposure (revenue-currency) | UNKNOWN | No revenue-geography data for any holding; listing currency (100% SEK on the 7 direct stocks) would mislead if substituted |
| Single-position concentration (15% cap) | WATCH | Avanza Global = 56.5% of investable capital — breaches literally, but it's itself a ~1,500-name diversified global index fund, not idiosyncratic stock risk; largest actual single stock AZN.ST is 7.0%, clean |
| Institution concentration (80% cap) | ACT | Avanza = 88.2% of investable capital (83.7% of full net worth) — breaches either way computed; structural to running one Swedish ISK broker on a sub-250k portfolio, not fixable by trimming individual holdings |
| Fee drag (0.4% cap) | OK | 187.12 SEK/yr = 0.088% of investable capital; worst offender Auto3 at 0.39%/yr, still under the 0.5% replacement-flag line |
| Wrapper efficiency | OK | ISK/KF capital ≈187,484 SEK vs ~300,000 SEK allowance (verify current threshold with Skatteverket); no AF inefficiency remains, only the frozen immaterial SEB Osteuropafond outside ISK, unsellable (Ukraine conflict), not actionable |
| Drawdown-tolerance fit | WATCH | On-file backtest -20.62% max DD (2019-2026) vs -30% tolerance (OPEN_ITEMS S26, still open, no fresh backtest run this sweep); the figure's own test window's worst equity shock was only -19.14%, i.e. inside tolerance but not stress-tested against anything tolerance-sized |

Exposure (investable 212,510 SEK): Equity 163,442 / Crypto 21,551 / Gold 5,689 / Cash 15,352 / FI-alt 6,476.

**One correction to the lens.** S26 is not "still open". It was closed under cap pressure on 10-26, with its fix fully specified and unapplied. The substance (no real shock-window backtest) stands.

**Provisional, per `investor_profile.json` (read this session):**
- `primary_goal` is "nature UNCERTAIN", on a 3–7y SOFT horizon.
- `constraints.exclusions` is `[]` ("None stated yet").
- `reference_targets` reads 85/10/0/5 with no `gold_pct`. **S35 is still unapplied, and per OPEN_ITEMS I have not re-derived it.**
- The −30% tolerance has never been tested against a real shock.

---

## 5. Headline calls

Each needs a decision this session.

1. **NVDA stays BUY, 1 share (~1,785 SEK), after a −15% week.** *Confidence Medium, horizon Medium.* The 11-17 print is the test. Macro's objection is regime-only and is stated as such.
2. **Execute P3, now unexecuted for a 14th sweep, then the rewritten queue. AZN.ST and SHB-A.ST leave it.** *P3: confidence High, horizon Long. Queue: Medium, Medium.*
   - **Funds available:** net deployable ≈ 14,506.92 × 0.96 + 845 = **~14,772 SEK**. The spread costs ~580 SEK (my arithmetic on `portfolio`'s figures).
   - **The queue, in order:**
     - (a) Gold tranche 2, ~4,930 SEK (`portfolio`; closes the 5% gap)
     - (b) NVDA, 1 share, ~1,785
     - (c) Remainder, ~8,056, to Avanza Global
   - **After the queue, the direct sleeve reads** (my arithmetic, on 35,513.60):
     - Sweden 43.9%, back under 45%
     - Healthcare 41.9%
     - **Industrials 46.6%, still ACT**
   - Clearing Industrials needs ~1,300 SEK more of a *non-industrial* direct stock. That is a reason to re-test MPC next sweep, not to force a buy now.
3. **ABB.ST: NO ACTION stands. None of the three reinstatement observables fired.** *Confidence Low, horizon Medium.* `thesis-review`'s BROKEN is the argument already weighed last week.
4. **Make the record edits in `portfolio.json` and `investor_profile.json`.** *Confidence High, horizon Long.* Two are carried over unapplied:
   - ABB BROKEN → WEAKENING
   - VOLV TOO_EARLY → INTACT

   Two are new or standing:
   - **AZN INTACT → WEAKENING** (captured upside, not deterioration)
   - **"apply S35"**

---

## 6. Open actions vs open decisions

### Open actions (things to go do), by ID

| ID | Status | Action |
|---|---|---|
| **P3** | decided — pending execution (14th sweep) | Convert 1,177.49 USD + 266.88 EUR (~14,507 SEK at this sweep's FX) inside PayPal, move it to the ISK, then run the §5 queue. It blocks gold tranche 2 and NVDA. |
| **P1** | blocked (on you) | ETH cost basis. Blocks any sale or K4, and keeps the no-adds freeze. |
| **P9** | open | Delete the phantom AZN OPENING row in the Excel Transactions tab. |
| **P10** | open | Confirm whether there was one 5,000 SEK deposit or two (08-17 vs 08-22). |
| **S35** | open, ready | "apply S35". Not re-derived. |
| **S27** | blocked (outside repo) | Re-sync the scheduled prompt. The two stale premises recurred again this week. |
| **S39 / S1** | open / standing | Fund NAVs are 15–16 weeks stale (~136k SEK). BTC0E.AS and Xetra-Gold returned 404 for a 5th sweep. |
| — | record edits | ABB.ST BROKEN → WEAKENING; VOLV-B.ST TOO_EARLY → INTACT; AZN.ST INTACT → WEAKENING. |

On DE000A0S9GB0: last week I recommended TOO_EARLY → INTACT. This week's `thesis-review` keeps TOO_EARLY ("testing requires a systemic-stress event"). A VIX-28 week is a moderate stress test it cannot be scored on, because there is no price. Leave it TOO_EARLY until a price exists.

### Open decisions (forks)

**D-a — ABB.ST.** Chairman pick: Option 1.
- *Option 1 — hold, no action.* Trade-off: you keep the richest multiple held, in an ACT sector, on a growth-adjusted case. A SELL comes back only on the three observables.
- *Option 2 — sell all 4 shares (~3,243 SEK) to cash.* Trade-off: Sweden rises to ~51.2%, cash is already over target, and you act on an argument that has not changed since last week.

**D-b — INVE-A.ST NAV.** Unchanged. Durable hold until you record a NAV figure.

**D-c — crypto sizing (BTC0E.AS has no price, 5th sweep).**
- *Option 1 — read the live Avanza value of your 150 units now.* Trade-off: one minute of your time.
- *Option 2 — record it, then scale it weekly by CoinGecko BTC spot.* Trade-off: proxy error on a 0%-fee backed note.
- *Option 3 — wait for a feed.* Trade-off: a 6th unsizable sweep.
- **Pick: Option 1, then Option 2.** BTC is −4.5% week on week and −9.9% over 30 days, so the carried 11,031 SEK mark is probably stale-high. That moves *away* from last week's ~14,802 SEK trim trigger, not toward it.

### Structural decisions (non-stock)

Levers 1–2 are closed. Note: CLAUDE.md's priority list still names the 2.5% BTC certificate (P4) as the open fee item. P4 closed on 2026-08-17. That text is stale, and I have not edited the doc.

**ACTION:** Execute P3. Recommended only; this system trades nothing.
- **POSITION:** ~14,507 SEK in PayPal, outside any wrapper.
- **TARGET:** the ISK, split per §5 call 2.
- **REASON:** it is the funding constraint on the only BUY and on the gold gap, and the ~4% spread recurs on every inflow.
- **THESIS STATUS:** decided by you 2026-08-17 (Option A).
- **WHAT CHANGED:** the queue got shorter (AZN and SHB withdrawn), and the count reached a 14th sweep.
- **BREAK CONDITION:** a fee-free route appears, or the realised spread is materially above 4%.
- **CONFIDENCE:** High
- **HORIZON:** Long

**ACTION:** Gold tranche 2, ~4,930 SEK of Xetra-Gold (DE000A0S9GB0), the first call on P3.
- **POSITION:** 5,689.22 SEK at cost (2.7%), no live price.
- **TARGET:** 5% (`portfolio.json.targets`), ceiling 7.5%.
- **REASON:** the structural crash hedge is under target in a regime `macro-regime` calls risk-off.
- **THESIS STATUS:** TOO_EARLY (`thesis-review`).
- **WHAT CHANGED:** VIX 28.18. This is the regime the carve exists for.
- **BREAK CONDITION:** a backtest shows gold adds nothing at 5% (the S26 fix).
- **CONFIDENCE:** Medium
- **HORIZON:** Long

---

## 7. Cost of being wrong

| Headline call | If wrong | Realistic SEK downside | Recoverable? |
|---|---|---|---|
| 1. NVDA BUY 1 share | The sell-off was the early warning, and NVDA falls another 40% | ~714 (1,785 × 0.40) | Yes. Sellable any day inside the ISK. |
| 2. P3 + rewritten queue | The spread is certain. Then gold −20% and Avanza Global −30%. Withdrawing AZN/SHB forgoes +20% on 1 and 10 shares | ~580 spread + ~986 + ~2,417; ~372 + ~322 foregone | The spread, no (it recurs while P3 waits). The rest, yes, with time. ~4,000 total, ~1.9% of capital. |
| 3. ABB NO ACTION | Margin compression shows up, and ABB −25% | ~811 (3,243 × 0.25) | Yes. |
| 4. Record edits / S35 | A status you later disagree with | 0 SEK, a one-line revert | Yes. |

All figures are my arithmetic on this sweep's prices and FX.

---

## 8. Timing collisions

From `20261109-events.json`. Macro dates were last verified 2026-08-03, and US/SE CPI dates are missing.

- **11-10 (tomorrow): Riksbank minutes.** No call depends on them.
- **11-17: NVDA reports.** This falls inside the likely P3 execution window. Buying before means owning the print. That is acceptable at a Medium horizon; do not time it.
- **11-30:** Riksbank FSR.
- **12-08/09: FOMC.** **AVGO reports on 12-09, FOMC day 2.** This is a collision for Contrarian's only focus pick. No action is attached.
- **12-16:** Riksbank decision.
- **12-23:** MU reports.
- **Further out:** MA and WDC on 01-28, MPC on 02-02. All are outside the window.

**One correction to the relayed calendar note.** The relay calls the past dates for ECHO (11-03) and FIS/TPL/APP (11-04) a possible widening of the staleness pattern. Those are the prints that **just happened**: APP's results are visibly in this week's data (#4). The simpler explanation is that Yahoo returns the *last reported* date until the next one is scheduled. That may also explain the Swedish pattern (10-20 to 10-30 prints), rather than staleness. Worth testing before `meta` treats it as a new defect.

---

## 9. Data gaps for `meta`

Ordered by what each cost this sweep. Surfaced, not fixed.

1. **The P/E fields are not time-aligned with `price` on fast movers. This is new, and it is quantified in §2.** Five names show identical percentage moves in implied trailing and forward EPS, from −6.2% to −16.4%. The quoted multiples on this week's fallers are overstated by about that much. Ratios are unaffected. A check that flags `|Δtrailing EPS − Δforward EPS| < 0.5pp` alongside a large price move would surface it.
2. **Copycat had no data on any non-holding.**
   - SEC EDGAR returned 403 again (CIK mapping).
   - FI is scoped to holdings only.
   - Add exact FI issuer names for the focus set, e.g. "Avanza Bank Holding", "Wihlborgs Fastigheter", "Diös Fastigheter".
3. **A lens re-counted old insider rows as new.** `thesis-review` read the 27/10 SHB and Volvo trades as "larger volumes". They sum to the same 1.6M and 1.5M counted last week. A "first seen in snapshot" flag per FI row would stop this.
4. **S36 recurred.** OPEN_ITEMS closed S36 on 11-02 with an explicit instruction: "Reopen (fresh ID) on the next `bs4`/FI-insider dependency failure, and apply the one-line `session-start.sh` fix." This sweep is that failure. The relay calls it "S36"; per the file it needs a **fresh ID** and the fix applied.
5. **The ABB board-fee pattern appeared a second time.** Ten directors traded at an identical price on one date. `thesis-review` read it correctly as compensation, but miscounted it as 11 directors. This is the second instance the "Considered, not opened" note was watching for. The proposed filter (3+ insiders, same price, same date → "scheduled") is now on two occurrences.
6. **No commodity or crack-spread data**, while four energy names entered at once (MPC, VLO, APA, EOG). This blocks a genuinely first-seen candidate (#5).
7. **The calendar "past date" may just be the last reported date** (§8). Test it before opening an item.
8. **The macro block runs at two speeds.** FX dates from 10-30, before the VIX spike. Fed funds is a monthly average, so the 10-28 FOMC outcome is not cleanly in it.
9. **Standing gaps:**
   - S39: fund NAVs stale 15–16 weeks
   - S1: BTC0E.AS and Xetra-Gold 404, 5th sweep
   - S21: AZN `forward_pe` missing, 12th run
   - S32: TSM FCF 61.78% unflagged; AZN/ABB unit mismatch
   - S38: the `new` label
10. **Net margin above op margin (a trailing-EPS quality marker), recurring:**

    | Name | Net margin | Op margin |
    |---|---|---|
    | ECHO | 81.3 | 13.8 |
    | CPT | 71.1 | 15.6 |
    | WDC | 69.2 | 47.7 |
    | GOOGL | 50.0 | 31.8 |
    | FIS | 26.8 | 22.9 |

    Scout could flag this the way `suspect` works.
11. **Repo hygiene (orchestrator-relayed).** Last week's sweep sat on a detached HEAD, and `check_unmerged_work.py` reported "Clean" because it only checks named branches. That is S34-shaped: a mandatory step verified by luck.
12. **CLAUDE.md is stale on P4** (§6), and the `portfolio` lens is stale on S26 (§4).

---

## 10. Learning notes

- **When both P/E legs move by exactly the same percentage, earnings did not change. The price used to compute them did.** Forward and trailing EPS cover different years, and analysts do not cut both by the identical amount. When NVDA's two implied EPS figures both fell 6.8%, the honest reading is "the market fell, the estimates did not". That is what kept the BUY alive. APP's two legs diverged (−7% vs −16%), and that divergence is what held it to WATCH.
- **A very low P/E at the top of a cycle is the market saying earnings will fall.** SNDK at 6.7x and MU at 9.3x looked like the cheapest quality in the file, and they fell 39% and 30% in a week. With 80% operating margins on a memory product, the multiple is low *because* the margin is expected to revert. Without data on memory prices, "cheap" has nothing under it.
- **Insider evidence ages, and it must be counted once.** The Handelsbanken chairman's ~245M SEK purchase was strong evidence on 11-02. This week it is the same trade, a week older, with the price 5% above where he bought. The same fact cannot justify a higher conviction twice. That is why the SHB add came out of the queue.
- **A detached HEAD is invisible to a branch check.** Commits made while not on a branch belong to no branch name. A script that loops over branches will report "clean" while those commits sit unpushed. That is exactly what happened to last week's sweep.

---

`journal` **must run next.** An unlogged memo is invisible to the next session and can never be reconciled. Then run:
- `python scripts/decisions.py record --picks data/picks/2026-11-09-picks.csv`
- `python scripts/decisions.py basis --write`
